We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
With several new regimens nearing late-stage trials, a new generation of HIV antiretrovirals may soon be entering the marketplace.
Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...
2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...
The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.
Two studies presented at IDWeek 2017 looked at patient and provider issues that impact retention in care and offered new insights that might help end disparities in the HIV care continuum.
Low dietary calcium might contribute to low bone mineral density (BMD) in men living with hepatitis C but not in those with HIV, according to a Veterans Administration analysis.
A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.
The majority of HIV-positive people with a statin indication by current guidelines are not receiving a statin, according to an analysis at a St. Louis HIV clinic.
In the years 2011-2013 people 45 or older acquired HIV infection at a frequency similar to that of younger people in New York City, San Francisco, and North Carolina.